Future studies should assess TRESK/TREK co-expression and also whether MT2 expressed at endogenous levels in human nociceptors results in TREK-1/2 inhibition and the relative contribution made by down-regulation of wild-type TRESK and TREK-1/2 to migraine pathogenesis. Here, KCNK18 is linked to migraine disorder.